HSBC Holdings
JNCE

HSBC Holdings’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

HSBC Holdings’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-14,464
Closed -$48K – 3239
2019
Q3 		$48K Buy
+14,464
New +$57.9K ﹤0.01% 3020
2017
Q2 		– Sell
-11,620
Closed -$256K – 2296
2017
Q1 		$256K Buy
+11,620
New +$246K ﹤0.01% 1886

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HSBC Holdings's JNCE Position: Q4 2019 in Review

HSBC Holdings sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2019, closing a stake of 14,464 shares — an estimated $48K sold.

HSBC Holdings first reported a position in JNCE in Q1 2017 and held it in 2 quarters. The position peaked at $256K in Q1 2017. 100 funds tracked by Wall St. Rank hold JNCE as of Q4 2019.

  • HSBC Holdings reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • HSBC Holdings sold 14,464 Jounce Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $48K.
  • HSBC Holdings first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • HSBC Holdings's Jounce Therapeutics, Inc. Common Stock position peaked at $256K in Q1 2017.
  • 100 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2019.

Based on HSBC Holdings's 13F filing for Q4 2019, filed 14 Feb 2020.